Incyte Corporation (INCY)

Market Cap	20.12B +41.6%
Revenue (ttm)	5.14B +21.2%
Net Income	1.29B +3,845.0%
EPS	6.41 +4,173.3%
Shares Out	199.01M
PE Ratio	15.77
Forward PE	13.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,370,632
Open	101.47
Previous Close	100.75
Day's Range	100.53 - 103.18
52-Week Range	53.56 - 112.29
Beta	0.85
Analysts	Buy
Price Target	100.58 (-0.51%)
Earnings Date	Feb 10, 2026

About INCY

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 4, 1993
• Employees: 2,844
• Stock Exchange: NASDAQ
• Ticker Symbol: INCY
• Website: https://www.incyte.com

Financial Performance

In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.

Analyst Summary

According to 21 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $100.58, which is a decrease of -0.51% from the latest price.

Price Target

$100.58

(-0.51% downside)

Analyst Consensus: Buy